Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1992-06-11
1994-02-08
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514 17, 5147726, 514549, 514400, A61K 31165, A61K 3702
Patent
active
052848760
ABSTRACT:
This invention pertains to a method for treating a subject for Tardive Dyskinesia by administering a dopaminergic agent to the subject such that the dopaminergic agent enters the brain or by administering a prodrug of a therapeutic agent. The dopaminergic agent preferably is 2 prodrug formed by coupling dopamine to a fatty acid. This invention further pertains to methods of providing pharmaceutical preparations and packaged pharmaceuticals for Tardive Dyskinesia.
REFERENCES:
patent: 4346085 (1982-08-01), Growdon et al.
patent: 4351831 (1982-09-01), Growdon et al.
patent: 4550109 (1985-10-01), Folkers et al.
patent: 4554272 (1985-11-01), Bock et al.
patent: 4636494 (1987-01-01), Growdon et al.
patent: 4684646 (1987-08-01), Chang et al.
patent: 4933324 (1990-06-01), Shashoua
patent: 4939174 (1990-07-01), Shashoua
T. Higuchi et al., "Prodrugs as Novel Drug Delivery Systems", American Chem. Society, ACS Symposium Series, vol. 14, pp. 14-15 (1975).
S. Iwakami et al., "Inhibition of Arachidonate 5-Lipoxygenase by Phenolic Compounds", Chem. Pharm. Bull. (Japan), 34(9), 3960-3963, 1986.
Y. Makino et al., Chemical Abstracts, vol. 106, No. 12, issued Mar. 23, 1987, "Pharmaceuticals Permeable to Blood-Brain Barrier".
G. Dhopeshwarker, Chemical Abstracts, vol. 76, No. 16, issued Apr. 17, 1972, "Fatty Acid Transport into the Brain".
R. Specter, Chemical Abstracts, vol. 108, No. 11, issued Mar. 14, 1988, "Fatty Acid Transport Through the Blood-Brain Barrier".
I. Yamatsu et al., Chemical Abstracts, vol. 100, No. 19, issued May 7, 1984, "Polyprenyl Carboxylic Acid Amides".
V. E. Shashoua, et al., ".gamma.-Aminobutyric Acid Esters.1. Synthesis . . . ", Journal of Medicinal Chemistry, vol. 27, No. 5, pp. 659-664 (1984).
J. N. Jacob, et al,, ".gamma.-Aminobutyric Acid Esters.2. Synthesis Brain Uptake . . . ", J. of Medicinal Chemistry, vol. 28, No. 1, pp. 106-110 (1985).
G. W. Hesse et al., "Inhibitory Effect of Cholesteryl .gamma.-Aminobutyrate" Neurolpharmacology, vol. 24, No. 2, pp. 139-146 (1985).
K. A. Jacobson et al., "Adenosine analogs with covalently attached lipids . . . ", FEBS Letters, vol. 225, Nos. 1, 2 pp. 97-102 (Dec. 1987).
A. Garzon-Aburbeh et al., "A Lymphotropic Prodrug of L-Dopa:Synthesis" J. Med. Chem. 29: 687-691 (1986).
U. K. Mazumdar & D. C. Dey, "Preparation and Evaluation of Ethambutol Derivatives", Indian J. Pharm. Sci. 47(6): 179-180 (1985).
R. J. Baldessarini et al., "Dopamine and the Pathophysiology of Dyskinesis . . . ", Ann. Rev. Neurosci. 3: 23-41 (1980).
J. P. Lohr et al., "Neuroleptic-Induced Movement Disorders . . . ", Psychiatry, vol. 3, (1989), J. B. Lippincott Co., Phila., Pa., ed. R. Michels.
J. N. Jacob et al., "Gamma-aminobutyris Acid Esters . . . ", J. Med. Chem. 30:1573-1576 (1987).
G. W. Hesse et al., "Uptake in Brain and Neurophysiological . . . ", Neuropharmacol. 27:637-640 (1988).
J. N. Jacob et al., "Synthesis, Brain Uptake and Pharmacological . . . ", J. Med. Chem. 33:733-736 (1990).
Hesse Gary W.
Shashoua Victor E.
Criares T. J.
Neuromedica, Inc.
Waddell Frederick E.
LandOfFree
Method of treating tardive dyskinesia using dopaminergic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating tardive dyskinesia using dopaminergic agents , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating tardive dyskinesia using dopaminergic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-698286